Martin Ehrbar

Prof. Dr. Martin Ehrbar

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2011 in Biophysical Journal
Verified
Journal Article
Closed access
MEMartin Ehrbar
Martin Ehrbar
ASA. Sala
A. Sala
PLP. Lienemann
P. Lienemann
ARA. Ranga
A. Ranga
KMK. Mosiewicz
K. Mosiewicz
MLMatthias Lutolf
Matthias Lutolf

30 April 2004 in Circulation Research
Verified
Journal Article
Closed access
PDF file
MEMartin Ehrbar
Martin Ehrbar
Valentin DjonovValentin Djonov
Valentin Djonov
CSChristian Schnell
Christian Schnell
STStefan A. Tschanz
Stefan A. Tschanz
GMGeorg Martiny-Baron
Georg Martiny-Baron
AZAndreas H. Zisch
Andreas H. Zisch
Although vascular endothelial growth factor (VEGF) has been described as a potent angiogenic stimulus, its application in therapy remains difficult: blood vessels formed by exposure to VEGF tend to be malformed and leaky. In nature, the principal form of VEGF possesses a binding site for ECM components that maintain it in the immobilized state until released by local cellular enzymatic activity. In this study, we present an engineered variant form of VEGF, α 2 PI 1–8 -VEGF 121 , that mimics this concept of matrix-binding and cell-mediated release by local cell-associated enzymatic activity, working in the surgically-relevant biological matrix fibrin. We show that matrix-conjugated α 2 PI 1–8 -VEGF 121 is protected from clearance, contrary to native VEGF 121 mixed into fibrin, which was completely released as a passive diffusive burst. Grafting studies on the embryonic chicken chorioallantoic membrane (CAM) and in adult mice were performed to assess and compare the quantity and quality of neovasculature induced in response to fibrin implants formulated with matrix-bound α 2 PI 1–8 -VEGF 121 or native diffusible VEGF 121 . Our CAM measurements demonstrated that cell-demanded release of α 2 PI 1–8 -VEGF 121 increases the formation of new arterial and venous branches, whereas exposure to passively released wild-type VEGF 121 primarily induced chaotic changes within the capillary plexus. Specifically, our analyses at several levels, from endothelial cell morphology and endothelial interactions with periendothelial cells, to vessel branching and network organization, revealed that α 2 PI 1–8 -VEGF 121 induces vessel formation more potently than native VEGF 121 and that those vessels possess more normal morphologies at the light microscopic and ultrastructural level. Permeability studies in mice validated that vessels induced by α 2 PI 1–8 -VEGF 121 do not leak. In conclusion, cell-demanded release of engineered VEGF 121 from fibrin implants may present a therapeutically safe and practical modality to induce local angiogenesis.

1 November 2010 in Biomaterials
Verified
Journal Article
Closed access
KBKatrin Bott
Katrin Bott
ZUZee Upton
Zee Upton
KSKarsten Schrobback
Karsten Schrobback
MEMartin Ehrbar
Martin Ehrbar
JHJeffrey A. Hubbell
Jeffrey A. Hubbell
SRSimone C. Rizzi
Simone C. Rizzi

13 October 2013 in Nature Materials
Verified
Journal Article
Closed access
KMKatarzyna A. Mosiewicz
Katarzyna A. Mosiewicz
LKLaura Kolb
Laura Kolb
AVAndré J. van der Vlies
André J. van der Vlies
MMMikaël M. Martino
Mikaël M. Martino
PLPhilipp S. Lienemann
Philipp S. Lienemann
MLMatthias P. Lutolf
Matthias P. Lutolf

21 September 2007 in Biomacromolecules
Verified
Journal Article
Closed access
MEMartin Ehrbar
Martin Ehrbar
SRSimone C. Rizzi
Simone C. Rizzi
RSRonald G. Schoenmakers
Ronald G. Schoenmakers
BMBlanca San Miguel
Blanca San Miguel
JHJeffrey A. Hubbell
Jeffrey A. Hubbell
MLMatthias P. Lutolf
Matthias P. Lutolf

3 June 2019 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
Paola OcchettaPaola Occhetta
Paola Occhetta
AMAndrea Mainardi
Andrea Mainardi
EVEmiliano Votta
Emiliano Votta
QVQueralt Vallmajo-Martin
Queralt Vallmajo-Martin
MEMartin Ehrbar
Martin Ehrbar
MRMarco Rasponi
Marco Rasponi